样式: 排序: IF: - GO 导出 标记为已读
-
Exploring the molecular mechanisms network of breast cancer by multi‐omics analysis Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-03-13 Wei Jiang, Yanjun Zhang, Qiuqiong Wang
BackgroundBreast cancer (BC), the most prevalent malignancy in women globally, still lacks comprehensive research on its molecular targets and necessitates further investigation into the underlying molecular mechanisms driving its initiation and progression.MethodsThe GSE20685 Series Matrix File downloaded from the Gene Expression Omnibus database was divided into a high‐risk group (n = 49) and a low‐risk
-
Cancer stem cell biomarkers SOX2 and Oct4 in cervical cancer patients undergoing chemoradiotherapy Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-02-26 Deep Chakrabarti, Sumaira Qayoom, Kirti Srivastava, Abigail Veravolu Resu, Divya Kukreja, Madhu Mati Goel, U. S. Singh, Naseem Akhtar, Shiv Rajan, Mranalini Verma, Rajeev Gupta, Madan Lal Brahma Bhatt
-
Colorectal cancer treatment outcomes during the pandemic: Our experience of COVID‐19 at a tertiary referral center Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-02-23 Christy Kei, Richard Gartrell, Yasser Arafat, Elizabeth Degabriele, Josephine Yeung, Steven Chan, Ian Faragher, Justin M. C. Yeung
-
Demographic and clinical profile of 1106 adult soft tissue sarcoma patients: A single institutional prospective database experience from India Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-02-22 Jyoti Sharma, Surya V. S Deo, Sunil Kumar, Sandeep Bhoriwal, Madhabananda Kar, Adarsh W Barwad, Sanjay Thulkar, Sameer Bakhshi, D. N. Sharma
BackgroundAdult soft tissue sarcomas (STS) are rare and diverse. Current management is based on limited literature from the West. Therefore, data from different geographical regions is required, including the low‐middle‐income countries. This is our experience managing adult sarcomas in the tertiary cancer center of North India.Materials and methodsThis is a retrospective analysis of the structured
-
The mechanisms of tumor necrosis factor α in regulating Krüpple-like factor 4 expression in SK-BR-3 breast cancer cells Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-01-18 Caiyun Liu, Chengbao Feng, Haifei Li, Erying Zhang, Bo Liu, Ying Wang, Peng Wang
-
Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-01-14 George Cavic, Andrew A. Almonte, Sarah M. Hicks, Teresa Neeman, Jo-Wai Wang, Sue Brew, Philip Y. Choi, Ian Cockburn, Elizabeth E. Gardiner, Desmond Yip, Aude M. Fahrer, Yada Kanjanapan
-
Diagnostic efficacy of combining diffusion-weighted magnetic resonance imaging with serum Mucin 1, Mucin 13, and Mucin 16 in distinguishing borderline from malignant epithelial ovarian tumors Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-01-14 Xiao-Ting Wen, Hai-Feng Qiu, Ling-Ling Ying, Min Huang, Yun-Zhou Xiao, Chen-Chen Fan
-
Overdiagnosis and overtreatment of ground-glass nodule-like lung cancer Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-01-04 Xinyu Liang, Chao Zhang, Xin Ye
-
A multidimensional assessment of payback: Evaluating the impact of Breast Cancer Trials Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2024-01-04 Ruth Knight, Belinda Luke, Renata Meuter, Kaitlin Peters, Kathleen Chell
-
Prevalence and risk factors of chemotherapy-induced oral mucositis among adult cancer patients at the cancer unit of Mbarara Regional Referral Hospital Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-12-26 Fredrick Atwiine, Julius Kyomya, Esther C. Atukunda, John Isiiko, Tadele Mekuriya Yadesa
-
Recommendations for the treatment and management of adult B-Cell acute lymphoblastic leukemia in Asia-Pacific: Outcomes from a pilot initiative Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-12-26 Zhentang Lao, Kwong Yok Lam, Yuk Man Carol Cheung, Chieh-Lin Teng, Vivek Radhakrishnan, Dinesh Bhurani, Bor-Sheng Ko, Yeow Tee Goh
-
The impact of targeted nursing intervention on postoperative medication adherence, quality of life, and psychological flexibility of thyroid cancer patients Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-12-07 Xiaohong Xu, Li Zhou, Wen Qiu, Yifang Su
-
Utility of survivorship care plans: A mixed-method study exploring general practitioners’ and cancer specialists’ views Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-12-05 Sim Yee Tan, Haryana M. Dhillon, Channel Mak, Roger Liang, Kim Kerin-Ayres, Kylie Vuong, Ashanya Malalasekera, Janette L. Vardy
-
Participation in oral health screening among cancer survivors. Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-11-23 In Cheol Hwang,Hong Yup Ahn
-
An Australian mainstream genetic testing program: Clinicians views about current and future practices Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-11-20 Alison Luk Young, Emilia Ip, Tahlia Scheinberg, Michelle Harrison, Philip Beale, Annabel Goodwin
-
Development and validation of Join Clinical Trial Questionnaire (JoinCT) Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-11-09 Shirin Hui Tan, Teck Long King, Shirley Siang Ning Tan, Wei Hong Lai, Mohamad Adam Bujang, Pei Jye Voon
-
Molecular profile of gastric adenocarcinoma, relevant epidemiological factors – Systematic review and meta-analysis relating sex with Epstein-Barr virus and unstable microsatellites subtypes Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-11-06 Gabriel Oliveira dos Santos, Warley Abreu Nunes, Waldemir Ferrari Júnior, Luiza Gomes Botega, Adriana Vial Roehe
-
Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-29 Yubao Huang, Yunkai Yang, Aidong Qu, Sixiu Li, Dandan Chen, Hongxia Zou, Songsong Li, Yaowen Zhang, Wei Zhuang, Jing Su, Xu Zhou, Yuntao Zhang
-
COSA President's Welcome Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Dear friends and colleagues, I am excited to welcome you to COSA's 50th ASM at the Melbourne Convention and Exhibition Centre. I'm so proud to be at the helm for COSA's 50th ASM. Some of you may recall that I had to step in for Fran Boyle last year when she required emergency surgery just before the 2022 ASM. So, I have a little bit of experience that helped set me up for this year and next. Firstly
-
Convenor Welcome Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
I am honoured to be convening the 2023 COSA ASM in my home town of Melbourne at the Melbourne Convention and Exhibition Centre from Wednesday 1 to Friday 3 November 2023. Just like everything else, the 2021 event that was originally planned for Melbourne was impacted by the pandemic and moved to a fully virtual conference, so we are now two years overdue. Our theme for the 2023 COSA ASM is 50 years
-
COSA committees Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
COSA PAST PRESIDENTS Mr WB Fleming AM (deceased) 11/1973–11/1976 Professor L Atkinson (deceased) 11/1976–11/1979 Dr RP Melville (deceased) 11/1979–11/1981 Professor MHN Tattersall AO (deceased) 11/1981–11/1983 Professor GJ Clunie (deceased) 11/1983–11/1985 Dr JVM Coppleson (deceased) 11/1985–11/1987 Professor JA Levi 01/1988–12/1989 Professor RM Fox AM 01/1990–12/1991 Professor WH McCarthy AM 01/1992–12/1993
-
Highlighted lectures and awards 2023 Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
TOM REEVE AWARD FOR OUTSTANDING CONTRIBUTIONS TO CANCER CARE This respected award, offered by COSA, formally recognises a national leader who has made a significant contribution over a relatively long period toward cancer care through research, clinical leadership, and/or community service. The award presentation and recipient's oration highlighting an overview of career achievements will be delivered
-
International speakers Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Dr Etienne Brain Institut Curie, France Etienne Brain, MD with a board certification in medical oncology (1993), works at Institut Curie since 1998. After a fellowship in Boston in 1996 (Dana Farber Cancer Institute and Boston University), he obtained a PhD in 2005. He was empowered to supervise research by Versailles/Saint-Quentin University in 2010. He got a diploma in Management and Health Economics
-
National speakers Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Dr George Au-Yeung Peter MacCallum Cancer Centre Dr George Au-Yeung is a clinician-researcher at Peter MacCallum Cancer Centre, and has a research interests in molecular biology of ovarian cancer as well as running novel biomarker driven clinical trials and translational research. He completed his PhD in Professor David Bowtell's laboratory, investigating novel therapeutic strategies for Cyclin E1
-
Program in Detail Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
WEDNESDAY 1 NOVEMBER, 2023 7:00–8:15 AM Breakfast Sessions Empowering excellence: advancing the quality and safety of gynaecological cancer care in Queensland 7:00–8:15 AM Meeting room 106 Chair: Rhett Morton 7:00 AM Rhett Morton Navigating the pathways: Patterns of care for all women with gynaecological cancer in Queensland abs# 1 7:15 AM Tamara Butler Ensuring equity: Monitoring health outcomes for
-
Poster Listing Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Leah Zajdlewicz Decisions and prompts to screen for cervical, bowel, and breast cancer abs# 160 Shalmoli Bhattacharyya Cancer-associated mesenchymal stem cells promote proliferation in chemo-radio-resistant cervical cancer cells abs# 161 Carina Chan Identifying MET exon 14 skipping mutations in squamous cell lung cancer patients abs# 162 Zoe Clarke Medical imaging simulated radiation therapy: Improving
-
Oral Abstracts Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
1 | Navigating the pathways: Patterns of care for all women with gynecological cancer in Queensland Rhett Morton1, Marcelo Nascimento2, Penny Mackenzie1, Kathryn Middleton3, Shaun McGrath3, Anna Kuchel1, Danica Cossio4, Victoria Donoghue4, Karen Sanday5, Neal Rawson4, Euan Walpole4,6, Andrea Garrett1 1Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia 2Gold Coast University Hospital
-
Poster Abstracts Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
160 | Decisions and prompts to screen for cervical, bowel and breast cancer Laura E Anderson1,2, Katelyn Collins1,3, Larry Myers1,3, Michael J Ireland3,4, Mariam Omar1, Allanah Drummond3, Leah Zajdlewicz1, Belinda Goodwin1,4,5 1Cancer Council Queensland, Fortitude Valley, Queensland, Australia 2National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia
-
Author Listing Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Abo, S 237,59 Abousamra, A 433 Ackerman, I 253 Ackland, T 53 Adam, T 358 Adams, C 139 Adams, D 377 Adams, G 233 Adams, J 254 Adams, K 188 Adderley, H 42 Adlard, KN 198 Aga, A 189 Agar, M 164,356,433,434,450,451,452,514 Agar, MR 497 Ahern, E 305,306 Ahmadi, N 170,170,171,171 Ahmed, E 243 Ahn, M 199 Aitken, J 104,50 Aitken, JF 501 Akechi, T 491 Akhurst, T 515 Al Deleemy, M 219 Al-Mufti, T 300,318 Alamgeer
-
2023 COSA ASM Exhibitor Listing Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Organization Booth number Altera Health 22 AstraZeneca 31,32,33,34 Atridia 2 Australian Clinical Labs 13 Breast Cancer Network Australia 45 Breast Cancer Trials 44 Bristol Myers Squibb 39 + 40 Cancer Nurses Society of Australia 5 Canteen Youth Cancer Services 17 CarerHelp 9 COSA 54 + 55 Eisai 6 Elekta 53 Eli Lilly 51 + 52 eviQ – Cancer Institute NSW 14 Genetic Technologies 30 GSK 35 + 37 iCIMS 24 Juniper
-
2023 COSA ASM Exhibitor Profiles Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-26
Altera Digital Health A global healthcare IT innovator, Altera Digital Health develops and elevates technology to connect and inspire healthier communities. Our platform approach to our solutions is changing the way healthcare is delivered. By keeping the human user at the center of our design methodology, we are supporting caregivers and helping patients meet and exceed their wellness goals. Together
-
Retraction: LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1 Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-27
Retraction: Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. Asia-Pac J Clin Oncol. 2021;17:253-263. https://doi.org/10.1111/ajco.13451. The above article, published online on 20 October 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors-in-Chief, Professor Stephen Ackland
-
Quality of life after non-nerve-sparing, robot-assisted radical prostatectomy Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-18 Yasushi Nakai, Nobumichi Tanaka, Takeshi Inoue, Kenta Onishi, Yosuke Morizawa, Shunta Hori, Daisuke Gotoh, Makito Miyake, Kazumasa Torimoto, Kiyohide Fujimoto
-
Outcomes of endoscopic ultrasound-guided gastro-enterostomy for gastric outlet obstruction in a two-centre Australian Cohort (with video) Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-09-28 Martin Harb, Arvind Kamath, Gavin Marx, Saurabh Gupta
-
Re-re-biopsy? How much tumor is enough in the era of precision oncology? Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-10-02 Samuel Smith, Michael Boyer, Steven Kao
Precision oncology is the concept of molecular profiling of tumors to identify targetable mutations.1 This underpins the idea of personalized medicine. In order to identify such alterations, it has been necessary to sample and analyze tumor tissue obtained through biopsy. Next-generation sequencing (NGS) and other comparable methods have made it possible to quickly analyze these tumor samples for molecular
-
Challenges and opportunities in the implementation of advanced brachytherapy programs for cervical cancer in the Philippines Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-09-24 Warren Bacorro, Bianca Nikkola Olonan, Henri Cartier Co, Anna Maria Fineza-Dela Cruz
Cervical cancer is the second most common cancer cause of morbidity and mortality in Filipino women; the age-standardized annual incidence is 15.2 as of March 2023. The majority are diagnosed at a locally advanced stage and in the reproductive and working age group. This results in important treatment and productivity costs. The importance of image-guided and interstitial brachytherapy (BRT) in local
-
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-09-20 Howard Gurney, Timothy D. Clay, Niara Oliveira, Shirley Wong, Ben Tran, Carole Harris
-
Consumers’ experiences, preferences, and perceptions of effectiveness in using telehealth for cancer care in Australia Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-09-15 Annie Banbury, Monica Taylor, Liam Caffery, Carolyn Der Vartanian, Helen Haydon, Roshni Mendis, Kawai Ng, Anthony Smith
-
T-cell lymphoma patient harboring BCL11B mutations had favorable overall survival Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-08-27 Cunte Chen, Ling Huang, Sichu Liu, Xinmiao Jiang, Feili Chen, Xiaojuan Wei, Hanguo Guo, Xiangbo Zeng, Chengwu Zeng, Grzegorz K. Przybylski, Wenyu Li, Yangqiu Li
Molecular genetics serve a critical role in constructing risk stratification for hematological malignancies, but T-cell lymphoma (TCL) still lacks molecular genetic information for supplement risk stratification in predicting the prognosis of TCL patients. In the present study, we characterized the mutation patterns of B-cell leukemia/lymphoma 11B gene (BCL11B) and its prognostic importance in TCL
-
Efficacy of sesame oil versus placebo in the management of acute radiation-induced dermatitis in breast cancer patients: A double-blind randomized clinical trial Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-08-24 Dariush Moslemi, Sepehr Ramezany, Ali Akbar Moghadamnia, Saba Ebrahimian
-
Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-08-11 Danielle Klingberg, Susie Bae, Deborah Di-Xin Zhou, Hao-Wen Sim, Ruilin Cai, Antoinette Anazodo, Peter Grimison, Craig Lewis, Yeh Chen Lee
Ewing's family sarcoma (EFS) is an aggressive malignancy with a peak incidence in adolescents. Multimodal treatment involves surgery and/or radiotherapy, and chemotherapy typically with VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide). There is a paucity of data for the treatment of adults, with protocols extrapolated from the pediatric setting. This
-
Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-07-17 Kwonoh Park, Hyun Jung Lee, Tae Un Kim, Hwaseong Ryu, Yong Kan Ki, Yun Jeong Hong, Jong Kil Nam
-
Clinicopathological and treatment response characteristics of updated rhabdomyosarcoma histomolecular subtypes: An Asian population-based study Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-07-11 Guo Yuan How, Chik Hong Kuick, Min Hwee Yong, Shui Yen Soh, Esther XY Hee, Meng Kang Wong, Richard Quek, Mohd Farid Harunal, Sathiyamoorthy Selvarajan, Kesavan Sittampalam, Chetan Anil Dhamne, Victor Lee, Kenneth TE Chang, Amos HP Loh
New histomolecular subtypes of rhabdomyosarcoma have recently been defined but their corresponding clinical characteristics are not well described. Also, these clinical phenotypes vary greatly by age and ethnicity but have not been profiled in Asian populations. Thus, we sought to determine the landscape of rhabdomyosarcoma subtypes in a national Asian cohort and compare clinical characteristics among
-
C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-07-06 Vanessa F. Bonazzi, Lauren G. Aoude, Sandra Brosda, Julia J. Bradford, James M. Lonie, Kelly A. Loffler, Michael G. Gartside, Kalpana Patel, Pamela Mukhopadhyay, Colm Keane, Val Gebski, James G. Kench, David Goldstein, Nicola Waddell, Andrew P. Barbour
-
A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-07-05 Yao Liang, Osamu Maeda, Kazushi Miyata, Chie Tanaka, Mitsuro Kanda, Dai Shimizu, Masahide Fukaya, Masahiko Koike, Yasuhiro Kodera, Yuichi Ando
-
Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non-small cell lung cancer Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-07-05 Choong-Won Lee, Byoung Hyuck Kim, Hong-Gyun Wu, Hak Jae Kim
-
Factors beyond diagnosis and treatment that are associated with return to work in Australian cancer survivors—A systematic review Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-25 Danielle Forbes, Karolina Lisy, Colin Wood, Victoria White, Sue Evans, Nina Afshar, Eli Ristevski, Arun Sharma, Krisha Changrani, Michael Jefford
-
Management of rectal cancer in the era of total neoadjuvant therapy and watch and wait: A multidisciplinary team discussion at the Australasian Gastro-Intestinal Trials Group (AGITG) Annual Scientific Meeting 2022 Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-21 Ankit Jain, Kirsten L. Gormly, Tamara Glyn, Tarik Sammour, Eugene J. Koay, Andrew Oar, Michael B. Jameson, Elizabeth C. Smyth, Sina Vatandoust
-
Does the number of cycles of neoadjuvant therapy affect the efficacy of neoadjuvant chemoimmunotherapy for non-small cell lung cancer in locally advanced stage? Retrospective experience based on a single center Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-14 Di Zhu, Zhida Huang, Kai Xiao, Dongliang Bian, Jing Zhang, Zhonghong Zhang, Shuncang Zhu, Laibo Yin, Jialong Zhu, Peng Zhang
-
Effect of multidisciplinary treatment (MDT) on survival outcomes of lung cancer patients: Experiences from China Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-08 Xiao-mei Jing, Ping Chen, Si-feng Li, Zi-rui Feng, Yin-feng Li, Qing Yang
-
The molecular characteristics of non-small cell lung cancer in the Northern Territory's Top End Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-05 Teesha Dzu Fun Downton, Kristof Wing, Stevie Brooke Cosentino, Narayan V Karanth
-
Asia-Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia-Pacific region Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-06-01 Zhentang Lao, Eric Wai Choi Tse, Suporn Chuncharunee, Yok Lam Kwong, Andrew Wei, Bor Sheng Ko, Jin Seok Kim, Soo Chin Ng, Jianxiang Wang, Yeow Tee Goh
-
Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter? Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-22 Robert Yoon, Kate Wilkinson, Gabriel Gabriel, Nasreen Kadaan, Tara Roberts, Stephanie Lim, Ray Asghari, Cheok Soon Lee, Wei Chua, Weng Ng
-
Benefit of medial retropharyngeal nodal region sparing in nasopharyngeal carcinoma patients: the final answer? Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-22 Roger Sun, Pierre Blanchard
Comment on Mao YP, Wang SX, Gao TS, et al. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. The retropharyngeal lymph node region is considered, together with the level II lymph nodes, to be the first echelon nodes of the nasopharyngeal
-
Mesenchymal stem cells- an excellent therapeutic agent for cancer Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-16 Anjilikal TomyTomcy, Edakkadath Raghavan Sindhu
-
Combinatorial approach of immuno-proton therapy in cancer: Rationale and potential impact Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-16 Utpal Gaikwad, Jyoti Bajpai, Rakesh Jalali
-
Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-12 Yingjie Ma, Junxian Yu, Xiaoting Ma, Qin Li, Qiang Su, Bangwei Cao
-
18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-08 Kiattisa Sommat, Aaron Kian Ti Tong, Ashley Li Kuan Ong, Jing Hu, Sze Yarn Sin, Winnie Wing Chuen Lam, Wanying Xie, Yiu Ming Khor, Cindy Lim, Tze Wei Lim, Sathiyamoorthy Selvarajan, Fuqiang Wang, Terence Wee Kiat Tan, Joseph Tien Seng Wee, Yoke Lim Soong, Kam Weng Fong, Tiffany Hennedige, Thng Choon Hua
-
Misdiagnosis of primary dumbbell chordoma of the cervical spine Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-08 Hua Zhou, Xiaoxiong Yang, Renji Wang, Xiaoguang Liu, Zhongjun Liu, Feng Wei
-
Breast cancer characteristics and pathological prognostic determinants in indigenous Australians: Retrospective cohort study in the Northern Territory Asia Pac. J. Clin. Oncol. (IF 1.9) Pub Date : 2023-05-03 Justin Mencel, Hooi Wen Hong, Michail Charakidis, Adrian Pokorny, Emily Aldridge, Narayan Karanth